Demant A/S (OTCMKTS:WILYY) Hits New 1-Year High – Time to Buy?

Demant A/S Unsponsored ADR (OTCMKTS:WILYY) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $22.34 and last traded at $22.34, with a volume of 1400 shares. The stock had previously closed at $20.66.

Analyst Ratings Changes

Several research firms have recently commented on WILYY. Morgan Stanley upgraded shares of Demant A/S from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, June 23rd. Sanford C. Bernstein downgraded Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 17th. Zacks Research raised Demant A/S to a “hold” rating in a research note on Friday, June 26th. Finally, UBS Group cut Demant A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Demant A/S presently has a consensus rating of “Moderate Buy”.

Demant A/S Price Performance

The company has a fifty day simple moving average of $20.26 and a two-hundred day simple moving average of $17.32. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 1.65.

About Demant A/S

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.